 |
市場調査レポート
商品コード
1069141
高カルシウム血症治療の世界市場：薬剤タイプ別（ビスフォスフォネート、カルシトニン、グルココルチコイド、デノスマブ、カルシミメティックス、その他）、適応症別、流通チャネル別、地域別－規模、シェア、展望、機会分析（2021年～2028年）Hypercalcemia Treatment Market, by Drug Type (Bisphosphonates, Calcitonin, Glucocorticoids, Denosumab, Calcimimetics, and Others), by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| 高カルシウム血症治療の世界市場：薬剤タイプ別（ビスフォスフォネート、カルシトニン、グルココルチコイド、デノスマブ、カルシミメティックス、その他）、適応症別、流通チャネル別、地域別－規模、シェア、展望、機会分析（2021年～2028年） |
|
出版日: 2022年03月16日
発行: Coherent Market Insights
ページ情報: 英文 219 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
概要
高カルシウム血症治療薬の規制当局による承認の増加は、予測期間中の市場成長を促進すると予想されます。
当レポートでは、世界の高カルシウム血症治療市場について調査しており、市場展望、市場力学、市場分析、競合情勢など、包括的な情報を提供しています。
目次
第1章 調査目的・前提条件
第2章 市場の展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
- 市場スナップショット：薬剤タイプ別
- 市場スナップショット：適応症別
- 市場スナップショット：流通チャネル別
- 市場スナップショット：地域別
- コヒーレントオポチュニティマップ（COM）
第3章 市場力学、規制、および動向分析
- 市場力学
- 促進要因
- 抑制要因
- 市場機会
- 影響分析
- 主な開発
- パイプライン分析
- PEST分析
- 規制シナリオ
- 新製品の発売/承認
- 疫学
- 市場動向
第4章 世界の高カルシウム血症治療市場－COVID-19影響分析
- 経済的影響
- COVID-19疫学
- 臨床試験および医薬品開発への影響
- COVID-19と戦うための政府のイニシアチブ
第5章 世界の高カルシウム血症治療市場：薬剤タイプ別（100万米ドル）（2017年～2028年）
- 概要
- ビスフォスフォネート
- カルシトニン
- 糖質コルチコイド
- デノスマブ
- カルシウム受容体
- その他
第6章 世界の高カルシウム血症治療市場：適応症別（100万米ドル）（2017年～2028年）
- 概要
- 原発性甲状腺機能亢進症
- 悪性腫瘍の高カルシウム血症
- その他
第7章 世界の高カルシウム血症治療市場：流通経路別（100万米ドル）（2017年～2028年）
- 概要
- 病院薬局
- 小売薬局
- オンライン薬局
第8章 世界の高カルシウム血症治療市場：地域別（100万米ドル）（2017年～2028年）
- イントロダクション
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第9章 競合情勢
- Bayer AG
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Pfizer, Inc.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Novartis AG
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Dr. Reddy's Laboratories Ltd.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Amgen Inc.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Viatris Inc. (Mylan N.V.)
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Sun Pharmaceutical Industries Ltd.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Cipla Inc.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Actiza Pharmaceutical Pvt. Ltd.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Apotex Inc.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Crinetics Pharmaceuticals, Inc.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Alkem Labs
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Torrent Pharmaceuticals Ltd.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Glenmark Pharmaceuticals Ltd.
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Hikma Pharmaceuticals
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
- Slate Run Pharmaceuticals
- 企業のハイライト
- 製品ポートフォリオ
- 主なハイライト
- 財務実績
- 市場戦略
第10章 セクション
目次
Product Code: CMI3504
Hypercalcemia is a condition in which the blood calcium concentration is high. Calcium is important for carrying out normal functions of organs, muscles, cells, and nerves. It has a role in blood clotting and bone health as well. Hypercalcemia can make it hard for the body to carry out its normal functions. Extremely high levels of calcium can be life-threatening. Excess parathyroid hormone (PTH) is the main cause of hypercalcemia. If the patient is symptomatic or if the calcium level is higher than 15 mg/dL, even in asymptomatic patients, treatment for hypercalcemia is required. Increased extracellular fluid clearance, reduced gastrointestinal (GI) absorption, and decreased bone resorption are the goals of treating hypercalcemia.
Market Dynamics
The increasing regulatory approvals for hypercalcemia drugs are expected to drive the market growth during the forecast period. For instance, in November 2021, Endo International plc, a pharmaceutical company, announced that the shipping of its calcitonin salmon injection, USP, multi-dose vials (2 mL) had begun by its Par Sterile Products business. Moreover, it started shipping following the final U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application. Par's calcitonin salmon injection is therapeutically equivalent to the MIACALCIN injection provided by Viatris Inc., a global pharmaceutical company. The injection is intended for the early treatment of hypercalcemic emergencies when a rapid reduction in serum calcium is needed, in combination with other appropriate agents.
Key features of the study:
- This report provides in-depth analysis of the global hypercalcemia treatment market , and provides market size (US$ million) and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hypercalcemia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bayer AG, Pfizer, Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Amgen Inc., Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Pvt. Ltd., Apotex Inc., Crinetics Pharmaceuticals, Inc., Alkem Labs, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals, and Slate Run Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global hypercalcemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypercalcemia treatment market
Detailed Segmentation:
- Global Hypercalcemia Treatment Market, By Drug Type:
- Bisphosphonates
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
- Others
- Bisphosphonates
- Global Hypercalcemia Treatment Market, By Indication:
- Primary Hyperthyroidism
- Hypercalcemia of Malignancy
- Others
- Global Hypercalcemia Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hypercalcemia Treatment Market, By Region:
- North America
- Drug Type
- Bisphosphonates
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
- Others
- By Indication
- Primary Hyperthyroidism
- Hypercalcemia of Malignancy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- U.S.
- Canada
- Latin America
- Drug Type
- Bisphosphonates
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
- Others
- By Indication
- Primary Hyperthyroidism
- Hypercalcemia of Malignancy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Drug Type
- Bisphosphonates
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
- Others
- By Indication
- Primary Hyperthyroidism
- Hypercalcemia of Malignancy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Drug Type
- Bisphosphonates
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
- Others
- By Indication
- Primary Hyperthyroidism
- Hypercalcemia of Malignancy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Drug Type
- Bisphosphonates
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
- Others
- By Indication
- Primary Hyperthyroidism
- Hypercalcemia of Malignancy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- Drug Type
- Bisphosphonates
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
- Others
- By Indication
- Primary Hyperthyroidism
- Hypercalcemia of Malignancy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Bayer AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer, Inc.
- Novartis AG
- Dr. Reddy's Laboratories Ltd.
- Amgen Inc.
- Viatris Inc. (Mylan N.V.)
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Actiza Pharmaceutical Pvt. Ltd.
- Apotex Inc.
- Crinetics Pharmaceuticals, Inc.
- Alkem Labs
- Torrent Pharmaceuticals Ltd.
- Glenmark Pharmaceuticals Ltd.
- Hikma Pharmaceuticals
- Slate Run Pharmaceuticals
- Bayer AG
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Indication
- Market Snapshot, By Distribution
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Pipeline Analysis
- PEST Analysis
- Regulatory Scenario
- New Product Launch/Approval
- Epidemiology
- Market Trends
4. Global Hypercalcemia Treatment Market- COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact On Clinical Trial And Drug Development
- Government Initiatives To Combat COVID-19
5. Global Hypercalcemia Treatment Market, By Drug Type, 2017 - 2028, (US$ Million)
- Overview
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 - 2028
- Segment Trends
- Bisphosphonates
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Clodronate
- Etidronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Glucocorticoids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Denosumab
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Calcimimetics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
6. Global Hypercalcemia Treatment Market, By Indication, 2017 - 2028, (US$ Million)
- Overview
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 - 2028
- Segment Trends
- Primary Hyperthyroidism
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
- Hypercalcemia of Malignancy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
7. Global Hypercalcemia Treatment Market, By Distribution Channel, 2017 - 2028, (US$ Million)
- Overview
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 - 2028
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
8. Global Hypercalcemia Treatment Market, By Region, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2028
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Viatris Inc. (Mylan N.V.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Actiza Pharmaceutical Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Crinetics Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alkem Labs
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Glenmark Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Slate Run Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
